Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

BACKGROUND: Expectations that reestablishing and maintaining sinus rhythm in patients with atrial fibrillation might improve survival were disproved in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. This report describes the cause-specific modes of death in the AFFIRM treatment groups. METHODS AND RESULTS: All deaths in patients enrolled in AFFIRM underwent blinded review by the AFFIRM Events Committee, and a mode of death was assigned. In AFFIRM, 2033 patients were randomized to a rhythm-control strategy and 2027 patients to a rate-control strategy. During a mean follow-up of 3.5 years, there were 356 deaths in the rhythm-control patients and 310 deaths in the rate-control patients (P=0.07). In the rhythm-control group, 129 patients (9%) died of a cardiac cause, and in the rate-control group, 130 patients (10%) died (P=0.95). Both groups had similar rates of arrhythmic and nonarrhythmic cardiac deaths. The numbers of vascular deaths were similar in the 2 groups: 35 (3%) in the rhythm-control group and 37 (3%) in the rate-control group (P=0.82). There were no differences in the rates of ischemic stroke and central nervous system hemorrhage. In the rhythm-control group, there were 169 noncardiovascular deaths (47.5% of the total number of deaths), whereas in the rate-control arm, there were 113 noncardiovascular deaths (36.5% of the total number of deaths) (P=0.0008). Differences in noncardiovascular death rates were due to pulmonary and cancer-related deaths. CONCLUSIONS: Management of atrial fibrillation with a rhythm-control strategy conferred no advantage over a rate-control strategy in cardiac or vascular mortality and may be associated with an increased noncardiovascular death rate.

Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial.

BACKGROUND: Several trials support the usefulness of disease management (DM) for improving clinical outcomes in heart failure (HF). Most of these studies are limited by small sample size; absence of concurrent, randomized controls; limited follow-up; restriction to urban academic centers; and low baseline use of effective medications. METHODS AND RESULTS: We performed a prospective, randomized assessment of the effectiveness of HF DM delivered for 90 days across a diverse provider network in a heterogeneous population of 200 patients with high baseline use of approved HF pharmacotherapy. During a 90-day follow-up, patients randomized to DM experienced fewer hospitalizations for HF [primary end point, 0.55+/-0.15 per patient-year alive versus 1.14+/-0.22 per patient-year alive in control subjects; relative risk (RR), 0.48, P=0.027]. Intervention patients experienced reductions in hospital days related to a primary diagnosis of HF (4.3+/-0.4 versus 7.8+/-0.6 days hospitalized per patient-year; RR, 0.54; P<0.001), cardiovascular hospitalizations (0.81+/-0.19 versus 1.43+/-0.24 per patient-year alive; RR, 0.57; P=0.043), and days in hospital per patient-year alive for cardiovascular cause (RR, 0.64; P<0.001). Intervention patients showed a trend toward reduced all-cause hospitalizations and total hospital days. On long-term (mean, 283 days) follow-up, there was substantial attrition of the 3-month gain in outcomes, with sustained significant reduction only in days in hospital for cardiac cause. CONCLUSIONS: In a population with high background use of standard HF therapy, a DM intervention, uniformly delivered across varied clinical sites, produced significant short-term improvement in HF-related clinical outcomes. Longer-term benefit likely requires more active chronic intervention, even among patients who appear clinically stable.

Review of antithrombotic agents used for acute coronary syndromes in renal patients.

Management issues in acute coronary syndromes (ACSs) with regard to patients with renal insufficiency or failure are complex. Renal patients have a greater risk for bleeding compared with those with normal renal function because of prolonged bleeding time and platelet dysfunction. Some of the drugs used have significant renal excretion, such as the glycoprotein IIb/IIIa receptor antagonists. Additionally, thrombolytics are underused, which contributes to the delay in instituting immediate treatment of acute myocardial infarction. Clinical data regarding the optimum management of ACSs in renal patients are still lacking. In this article, we review the available data on the use of antithrombotic agents, particularly in patients with renal impairment.

The Effect of Snoring on Atrial Septum.

While performing transesophageal echocardiograms, on two occasions we observed extreme atrial septal bulging into the left atrium during stertor.

Gender Differences in Mitral Inflow Parameters of Doppler Echocardiography.

BACKGROUND: Doppler echocardiographic parameters are useful in understanding cardiac function. Previous studies have evaluated the physiologic effects of heart rate, body position, and age on left ventricular (LV) Doppler inflow variables. OBJECTIVE: The aim of this study was to investigate the effect of gender on LV Doppler inflow variables. METHODS: A complete echocardiographic study was performed in the left lateral position on 25 male and 25 female normal subjects. The Doppler variables, of E and A wave velocities, acceleration and deceleration times of the E wave velocity, and cardiac chamber dimensions were measured. RESULTS: The aortic root size (3.2 +/- 0.4 vs 2.8 +/- 0.4 cm, P = 0.002), LV end systolic (2.8 +/- 0.3 vs 2.5 +/- 0.5 cm, P = 0.03), and LV end diastolic dimensions (5.0 +/- 0.4 vs 4.5 +/- 0.6 cm, P = 0.003) were larger in men compared to women. E wave deceleration time (233 +/- 40 vs 197 +/- 37 msec, P = 0.002) was longer in men compared to women. Using univariate analysis, deceleration time of the E wave was correlated with heart rate (P = 0.001), maximal A wave velocity (P = 0.007), acceleration time of the E wave (P = 0.01), LV systolic dimension (P = 0.03), maximal E wave velocity (P = 0.04), LV diastolic dimension (P = 0.06), and height (P = 0.07). E/A ratio, body surface area, age, weight, and left atrial dimension had no significant correlation with the deceleration time of the E wave. In the multivariate model, heart rate (P = 0.001) had the most significant (inverse) correlation with deceleration time of the E wave. CONCLUSIONS: In this cohort of subjects, there were significant differences in LV systolic and diastolic measurements and Doppler measurements of deceleration time of the E wave between men and women. The differences in Doppler measurements between men and women are most likely affected by the higher heart rate in women. Therefore, when interpreting deceleration time of the E wave, the effect of heart rate should be considered.

Stress Echocardiography: A Review of the Principles and Practice.

Stress echocardiography, both pharmacologic and physiological, is an established noninvasive diagnostic method of detecting coronary artery disease. It also has a role in the assessment of patients with chest pain, the assessment of cardiovascular risk before noncardiac surgery, the assessment of patients after a myocardial infarction, the detection of viability in dysfunctional myocardium, and the prediction of functional recovery. The prognostic value of stress echocardiography is emerging. In this article, we discuss the methodology, diagnostic accuracy, and various clinical applications of stress echocardiography. We also review its limitations and compared it with other noninvasive methods of assessing patients with coronary artery disease.

The incidence of diastolic right atrial collapse in patients with pleural effusion in the absence of pericardial effusion.

The aim of this study was to describe the incidence of cardiac chamber collapse assessed by echocardiography and explore possible mechanisms in a clinical population of 116 patients with pleural effusion in the absence of pericardial effusion. We found that the frequency of chamber collapse was 18% in patients with pleural effusion in the absence of pericardial effusion, thus cardiac chamber collapse occurs in patients with pleural effusion.

The use of stress echocardiography in the assessment of mitral valvular disease.

Stress echocardiography plays an important role in evaluating asymptomatic patients with significant mitral stenosis and symptomatic patients with only mild disease at rest, as it correlates the exercise-induced symptoms with changes in transmitral gradients, pulmonary pressures, and mitral valve area. In patients with mitral regurgitation (MR), exercise or dobutamine protocols assess for the change in the degree of regurgitation and the pulmonary artery pressure (PAP) in response to high flow states, and detect underlying left ventricular (LV) dysfunction prior to valvular surgery. Exercise echocardiography also helps in the prognostic assessment of patients with mitral valve prolapse as new MR, or latent LV dysfunction may be provoked to identify a group of high risk individuals with normal resting echocardiographic parameters. Finally, it evaluates the proper functioning of prosthetic mitral valves and helps on the monitoring of transmitral gradients and PAPs after mitral valve surgery.

Evaluation of aortic valve disorders using stress echocardiography.

Stress echocardiography is a safe and valuable test to aid in the diagnosis and management of patients with aortic valve disorders. In patients with suspected severe aortic stenosis (AS) and low aortic gradients secondary to low cardiac output, dobutamine echocardiography distinguishes those patients with contractile reserve (CR) from those without it. By increasing the stroke volume in subjects with CR, true severe AS patients have an increase in transaortic gradients without a significant change in the valve area, whereas patients with pseudostenosis have an increase in the gradients with concomitant increase in the aortic valve area to >1 cm(2). Patients without CR are indeterminate in their AS status and have a poor prognosis. The presence of CR is also important in patients suffering from aortic insufficiency, as it may predict the development of symptoms, myocardial dysfunction, or death in the asymptomatic phase of the disease, and the potential for left ventricular functional recovery after valve replacement. Finally, both exercise and dobutamine echocardiography can help in the assessment of valve malfunction or mismatch in patients with aortic valve prostheses experiencing exercise intolerance by correlating the symptoms with the change in the aortic gradients induced during stress testing.

Miscellaneous use of exercise echocardiography in patients with chronic pulmonary disease or congenital heart defect.

To date, the usage of exercise echocardiography in patients with pulmonary or congenital heart disease has been limited despite its potential for broader applications in different clinical scenarios. Exercise echocardiography can be utilized to determine the extent of pulmonary vascular damage in patients with chronic obstructive pulmonary disease by demonstrating the presence of exertional pulmonary hypertension in subjects with normal pulmonary artery pressures (PAPs) at rest. It is also useful in patients with connective tissue disease to screen for lung involvement by identifying exertional pulmonary hypertension, and in patients with established pulmonary hypertension to choose and monitor the effects of therapeutic interventions on the PAPs. Moreover, the measurement of aortic flow velocity and acceleration by exercise echocardiography may be helpful in the study of dyspnea in patients at risk for both pulmonary disease and congestive heart failure. In patients with congenital heart disease, the measurement of PAP and ventricular function both at rest and during exercise by echocardiography is the cornerstone in the investigation of the etiology of exercise intolerance in these individuals. Lastly, exercise echocardiography can also screen for residual narrowing in patients after repair of the coarctation of the aorta by detecting a significant diastolic gradient in the descending aorta during exercise provocation.

An overview of stress echocardiography in the study of patients with dilated or hypertrophic cardiomyopathy.

Stress echocardiography is a useful noninvasive modality for measuring dynamic outflow gradient and contractility changes in patients with hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM). In patients with HCM, stress echocardiography may determine the degree of outflow tract obstruction at rest and with activity, can detect occult systolic dysfunction in symptomatic patients with a normal resting left ventricular ejection fraction, and can also be utilized to monitor the efficacy of treatment. In individuals suffering from DCM, stress echocardiography is an important aid in the evaluation of the etiology, diagnosis, and prognosis of the disease as well as the functional status of the patient during either exercise or simulated stress conditions. Dobutamine stress echocardiography, by providing a measurement of the myocardial reserve, is a useful tool to predict the systolic recovery and clinical outcome of patients with heart failure. The stress-induced change in the wall motion score index can also be used as an accurate alternative to predict the peak oxygen consumption rate and exercise capacity of the same patient population. Finally, stress echocardiography has also been used in the identification of the predilated phase of cardiomyopathy in individuals with high clinical suspicion of the disease.